)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Summit Therapeutics
Summit Therapeutics (SMMT) investor relations material
Summit Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary19 Oct, 2026
Executive summary
Special meeting scheduled virtually for November 4, 2026; record date October 1, 2026, with 799,726,418 common shares outstanding and entitled to vote.
Stockholders will vote on raising authorized common shares by 1 billion, from 1 billion to 2 billion; the board unanimously recommends approval.
Voting matters and shareholder proposals
Proposal 1 requires approval by a majority of votes cast; abstentions and broker non-votes have no effect, and brokers may vote uninstructed shares because the proposal is routine.
Votes by Internet or telephone are due by 11:59 p.m. ET November 3, 2026; stockholders may also vote during the virtual meeting.
Rule 14a-8 proposals for the 2027 annual meeting must be received by December 18, 2026; advance-notice and universal-proxy deadlines also apply to nominations and other business.
Board of directors and corporate governance
The board unanimously adopted the charter amendment as advisable and in stockholders’ best interests, and recommends a FOR vote.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Summit Therapeutics
- A 1 billion-share authorization increase is tied to a $2 billion preferred financing.SMMT
Proxy filing - Ivonescimab's phase III successes position it as a potential game changer in solid tumor therapy.SMMTThe Citizens Life Sciences Conference 2026
- Ivonescimab achieved landmark Phase III survival results, FDA BLA acceptance, and strong cash reserves.SMMTQ2 2026
- Ivonescimab shows superior efficacy and safety in NSCLC, driving global phase III trials.SMMTCiti's 2024 Global Healthcare Conference
- Ivonescimab's global trials show strong efficacy, with pivotal filings and new indications advancing.SMMTJefferies London Healthcare Conference 2025
- Ivonescimab plus chemo cut death risk by 34% vs. tislelizumab in 1L squamous NSCLC.SMMTStatus update
- Ivonescimab's strong phase III data drive BLA plans, but urgent new funding is needed.SMMTQ3 2025
- Ivonescimab's strong Phase III results and $487M cash drive global clinical expansion.SMMTQ3 2024
- Ivonescimab's PFS benefit and China approval drive global trials, with $361M cash and no debt.SMMTQ1 2025
Next Summit Therapeutics earnings date
Q3 20262 Nov, 2026
Summit Therapeutics
Next Summit Therapeutics earnings date
Q3 20262 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Summit Therapeutics Inc., headquartered in Menlo Park, California, is a biopharmaceutical company engaged in the research and development of oncology therapies in the United States and the United Kingdom. Its lead pipeline product, ivonescimab, is a novel, bispecific antibody targeting both PD-1 and VEGF. Summit Therapeutics has also initiated two clinical trials with ivonescimab. Additionally, the company's product pipeline includes SMT-738, a novel class of precision antibiotics aimed at treating multidrug-resistant infections, including carbapenem-resistant Enterobacteriaceae infections. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.